Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + tiragolumab versus durvalumab after concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer
NL-OMON54439Phase 3Recruiting
- Sponsor
- Roche
- Start
- Jan 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atezolizumab, tiragolumab and durvalumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoint: Progression-free survival in the PD-L1-positive analysis set. Started Jan 2021; status: recruiting.
02
Drugs
atezolizumabtiragolumabdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON54439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54439.